{"nctId":"NCT00039871","briefTitle":"PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","startDateStruct":{"date":"2002-05"},"conditions":["Hepatitis","Hepatitis C, Chronic","Fibrosis","Liver Cirrhosis"],"count":2333,"armGroups":[{"label":"Overall study population","type":"EXPERIMENTAL","interventionNames":["Biological: PegIntron (peginterferon alfa-2b; SCH 54031)","Drug: REBETOL (ribavirin; SCH 18908)"]}],"interventions":[{"name":"PegIntron (peginterferon alfa-2b; SCH 54031)","otherNames":["SCH 54031"]},{"name":"REBETOL (ribavirin; SCH 18908)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age at entry 18-65\n* Positive for Hepatitis C\n* Nonresponder to previous treatment (minimum of 3 months) with an alpha Interferon plus ribavirin\n* Liver biopsy demonstrating moderate to severe fibrosis or cirrhosis\n\nExclusion Criteria:\n\n* Any cause for the liver disease other than chronic hepatitis C\n* History or presence of complications of cirrhosis\n* Alcohol or illicit drug use or methadone treatment within the past 2 years\n* Treatment for chronic hepatitis C within the previous 6 months\n* Diseases or conditions that could interfere with the subject's participation in and completion of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sustained Virologic Response (SVR) Rate","description":"Number of participants with undetectable hepatitis C virus RNA (HCV-RNA)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"497","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12","description":"Number of participants with undetectable HCV-RNA at Treatment Week 12 who had subsequent undetectable HCV-RNA after 24 weeks of posttreatment follow-up","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"463","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12","description":"Number of participants with detectable HCV-RNA but ≥2 log drop from baseline in HCV-RNA at Treatment Week 12 who had subsequent undetectable HCV-RNA after 24 weeks of posttreatment follow-up","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":200,"n":2312},"commonTop":["HEADACHE","PYREXIA","FATIGUE","MYALGIA","NAUSEA"]}}}